@article{12739,
      recid = {12739},
      title = {Patent protection and access to HIV/AIDS pharmaceuticals  in Sub-Saharan Africa.},
      pages = {v, 100 pages ;},
      abstract = {This report examines the role that patents play in access  to pharmaceuticals in the HIV/AIDS crisis of sub-Saharan  Africa. The report aims to provide unbiased information  about the international patent regime, the current patent  status of certain HIV/AIDS drugs in sub-Saharan Africa and  opportunities that exist through flexibility in  international patent law that may help to improve access to  HIV/AIDS drugs in that region. The report concludes that  providing state-of-the-art HIV/AIDS therapies to patients  in poor countries requires two kinds of subsidies. The  first is the indirect subsidy which consumers in developed  countries pay in the form of higher prices for patented  drugs. The patent incentive in countries such as the United  States induces the free market to test and develop new  products. Without the patent incentive, life- sustaining  AIDS therapies would simply be unavailable even to the  wealthiest consumers. The second kind of subsidy is direct  funding of the treatment infrastructure and the purchase of  drugs for patients in poor countries by the governments of  developed countries acting in concert with one another  through international programs such as UNAIDS.},
      url = {http://tind.wipo.int/record/12739},
      doi = {https://doi.org/10.34667/tind.12739},
}